Camurus

Camurus Tangible Book Value per Share

The Tangible Book Value per Share of Camurus (CAMX.ST) as of Nov 3, 2026 is 71.14 SEK. In the previous year, Tangible Book Value per Share was 55.15 SEK — a change of 28.98% (higher).

Tangible Book Value per Share

71.14SEK

YoY

28.98%

Last updated:

Tangible Book Value per Share of Camurus is 2025 71.14 SEK. Tangible Book Value per Share of Camurus was 2024 55.15 SEK. It decreases by 28.98% higher compared to the previous year.

The Camurus Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
3.99 SEK
Jan 1, 2019
10.03 SEK
Jan 1, 2020
13.69 SEK
Jan 1, 2021
13.76 SEK
Jan 1, 2022
16.47 SEK
Jan 1, 2023
24.82 SEK
Jan 1, 2024
55.15 SEK
Jan 1, 2025
71.14 SEK
The Camurus Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
71.14SEK+28.98%
55.15SEK+122.20%
24.82SEK+50.73%
16.47SEK+19.66%
13.76SEK+0.54%
13.69SEK+36.44%
10.03SEK+151.45%
3.99SEK-35.84%
6.22SEK-32.50%
9.21SEK-11.95%
10.46SEK+402.00%
2.08SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Camurus Stock analysis

What does Camurus do? Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Camurus stock

Tangible Book Value per Share of Camurus is 71.14 SEK in 2025.

Tangible Book Value per Share of Camurus changed from 55.15 SEK to 71.14 SEK, representing a 28.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Camurus since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Camurus

All Key Metrics — Camurus